These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30962742)

  • 1. Protective Effects of Ipragliflozin, a Sodium-glucose Cotransporter 2 Inhibitor, on a Non-alcoholic Steatohepatitis Mouse Model.
    Yamane M; Matono T; Okano JI; Nagahara R; Matsuki Y; Okamoto T; Miyoshi KI; Sugihara T; Nagahara T; Koda M; Isomoto H
    Yonago Acta Med; 2019 Mar; 62(1):30-35. PubMed ID: 30962742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules.
    Hosokawa K; Takata T; Sugihara T; Matono T; Koda M; Kanda T; Taniguchi S; Ida A; Mae Y; Yamamoto M; Iyama T; Fukuda S; Isomoto H
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31888083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling.
    Suga T; Sato K; Ohyama T; Matsui S; Kobayashi T; Tojima H; Horiguchi N; Yamazaki Y; Kakizaki S; Nishikido A; Okamura T; Yamada M; Kitamura T; Uraoka T
    World J Hepatol; 2020 Jul; 12(7):350-362. PubMed ID: 32821334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Expression Analysis of the Activating Factor 3/Nuclear Protein 1 Axis in a Non-alcoholic Steatohepatitis Mouse Model.
    Nagahara R; Matono T; Sugihara T; Matsuki Y; Yamane M; Okamoto T; Miyoshi K; Nagahara T; Okano JI; Koda M; Isomoto H
    Yonago Acta Med; 2019 Mar; 62(1):36-46. PubMed ID: 30962743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
    Honda Y; Imajo K; Kato T; Kessoku T; Ogawa Y; Tomeno W; Kato S; Mawatari H; Fujita K; Yoneda M; Saito S; Nakajima A
    PLoS One; 2016; 11(1):e0146337. PubMed ID: 26731267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
    Morishita A; Tadokoro T; Fujihara S; Iwama H; Oura K; Fujita K; Tani J; Takuma K; Nakahara M; Shi T; Haba R; Okano K; Nishiyama A; Ono M; Himoto T; Masaki T
    PLoS One; 2022; 17(2):e0261310. PubMed ID: 35192632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
    Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
    Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
    Tahara A; Takasu T
    Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
    Tahara A
    Eur J Pharmacol; 2021 Jun; 901():174076. PubMed ID: 33798599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice.
    Kishina M; Koda M; Kato J; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
    Hepatol Res; 2014 Aug; 44(8):888-896. PubMed ID: 23777387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty liver Shionogi-ob/ob mouse: A new candidate for a non-alcoholic steatohepatitis model.
    Sugihara T; Koda M; Kishina M; Kato J; Tokunaga S; Matono T; Ueki M; Murawaki Y
    Hepatol Res; 2013 May; 43(5):547-56. PubMed ID: 23057725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease.
    Miyake T; Yoshida S; Furukawa S; Sakai T; Tada F; Senba H; Yamamoto S; Koizumi Y; Yoshida O; Hirooka M; Kumagi T; Niiya T; Miyaoka H; Masanori A; Matsuura B; Hiasa Y
    Open Med (Wars); 2018; 13():402-409. PubMed ID: 30234161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.
    Takeda A; Irahara A; Nakano A; Takata E; Koketsu Y; Kimata K; Senda E; Yamada H; Ichikawa K; Fujimori T; Sumida Y
    Intern Med; 2017 Oct; 56(20):2739-2744. PubMed ID: 28924123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice.
    Matono T; Koda M; Tokunaga S; Kato J; Sugihara T; Ueki M; Murawaki Y
    Hepatol Res; 2011 Dec; 41(12):1240-8. PubMed ID: 21951423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance, steatohepatitis, and hepatocellular carcinoma in a new congenic strain of Fatty Liver Shionogi (FLS) mice with the Lep(ob) gene.
    Soga M; Hashimoto S; Kishimoto Y; Hirasawa T; Makino S; Inagaki S
    Exp Anim; 2010; 59(4):407-19. PubMed ID: 20660987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
    Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
    Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.
    Kristiansen MN; Veidal SS; Rigbolt KT; Tølbøl KS; Roth JD; Jelsing J; Vrang N; Feigh M
    World J Hepatol; 2016 Jun; 8(16):673-84. PubMed ID: 27326314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.